Search the Newsreel

Embecta Corp. 2026: Revenue $271.7M, EPS $0.36— 10-Q Summary

Embecta Corp. reported its 2026 quarter results with revenue of $271.7 million and diluted EPS of $0.36, marking a significant decrease from the prior year. The revenue decline was attributed to lower volume and pricing pressure, despite the acquisition of Owen Mumford. The company …

Earnings call transcript: Embecta beats Q3 2026 estimates, shares jump premarket

Earnings call transcript: Octave Specialty Group posts strong Q2 2026 growth

embecta Reports Third Quarter Fiscal 2026 Financial Results

Embecta Corp. announced its third-quarter fiscal 2026 financial results on August 7, 2026, holding a conference call and live webcast for analysts and investors. The company is transitioning from focusing solely on insulin delivery to becoming a broader medical supplies company. While the official …

Embecta reports Q3 FY2026 revenue $271.7M, GAAP net income $21.1M; raises adjusted EPS guidance

Embecta (EMBC) reported its Q3 FY2026 financial results, achieving revenues of $271.7 million and a GAAP net income of $21.1 million. The company posted adjusted diluted EPS of $0.56 and has raised its full-year adjusted operating margin and adjusted EPS guidance, while reaffirming full-year …

Embecta Corp. (Nasdaq: EMBC) Q3 2026 revenue dips as earnings outlook raised

embecta Sets Sept. 15 Payment Date for $0.01 Cash Dividend

embecta (Nasdaq: EMBC) has announced that its Board of Directors declared a quarterly cash dividend of $0.01 per share. The dividend is payable on September 15, 2026, to stockholders of record as of August 27, 2026. Following this news, EMBC's stock gained 27.29%, indicating …

embecta Announces Quarterly Cash Dividend

Embecta Corp. (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 per share. The dividend is payable on September 15, 2026, to stockholders of record as of August 27, 2026. Embecta is a global medical supplies company focused on insulin delivery and other …

FRACTAL ANALYTICS LIMITED (FRACTAL.NS) stock price, news, quote and history

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Embecta Corp. of Class Action Lawsuit and Upcoming Deadlines - EMBC

Pomerantz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who suffered losses. The lawsuit alleges securities fraud after Embecta missed its Q2 2026 guidance and lowered its fiscal year guidance, primarily due to weak pen needle …

Ambac Financial Group Non-GAAP EPS of -$0.04 misses by $0.03, revenue of $58M misses by $26.28M

* Ambac Financial Group press release [https://seekingalpha.com/pr/20611055-octave-specialty-group-reports-second-quarter-2026-results] (OSG [https://seekingalpha.com/symbol/OSG]): Q2 Non-GAAP EPS of -$0.04 misses by $0.03. * Revenue of $58M (+5.5% Y/Y) misses by $26.28M. MORE ON AMBAC FINANCIAL GROUP * Octave Specialty Group, Inc. 2026 Q1 - Results - Earnings Call Presentation …

Octave Specialty Group (NYSE: OSG) lifts revenue and narrows loss

Octave Specialty Group Q2 revenue rises 51 percent to $83 million

OCTAVE SPECIALTY GROUP ($OSG) Releases Q2 2026 Earnings, Stock Rises

EMBC Investors Have Opportunity to Lead Embecta Corp. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers. The lawsuit alleges that Embecta made false and misleading statements about its business and operations, particularly concerning its pen needle business and fiscal guidance, leading …

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 17, 2026 in Embecta Corp. Lawsuit - EMBC

Levi & Korsinsky, LLP is reminding Embecta Corp. (NASDAQ: EMBC) investors of a pending class action lawsuit with a lead plaintiff deadline of August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal year 2026 revenue guidance and U.S. pen …

Octave Specialty Group (NYSE: OSG) grows Q2 revenue 51% but stays in loss

Octave Specialty Group (OSG) Earnings Date and Reports 2026 $OSG

Octave Specialty Group (OSG) Reports Q2 Loss, Beats Revenue Estimates

Embecta Corp. (EMBC): Deeply Undervalued Global Medical Device Company

Embecta Corp. (EMBC), a global medical device company specializing in diabetes care, is highlighted as a potentially undervalued opportunity. Despite operating in a defensive healthcare sector with stable demand, EMBC trades at attractive valuation levels, boasting strong cash generation, resilient profitability, and an improving …

Will These 3 Insurance Stocks Insure a Q2 Earnings Beat?

As second-quarter 2026 earnings continue to roll in, the insurance sector is emerging as one of the early bright spots. Industry leaders Marsh, AON and Hartford have already cleared the bar, reporting results that topped expectations and offering investors a constructive read on the …

Levi & Korsinsky Reminds Embecta Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 17, 2026 - EMBC

Levi & Korsinsky, LLP is reminding Embecta Corp. (NASDAQ: EMBC) investors of a pending class action lawsuit with a lead plaintiff deadline of August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal year 2026 revenue guidance and U.S. pen …

Aarti Surfactants’ Q1 FY27 profit nearly triples on strong revenue growth

Kaplan Fox Deadline Alert: Embecta Corp. (NASDAQ: EMBC) Investors Have Until August 17, 2026 to Seek a Lead Plaintiff Role

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from a significant drop in Embecta's stock price after the …

Nectar Lifesciences Monetizes Non-Core Jammu Unit With Asset Sale

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A

Bernstein Liebhard LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its business, leading …

Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 9.99% in Cellectar Biosciences, Inc. (CLRB) through a Schedule 13G filing. This stake includes 864,090 shares, with 674,485 shares issuable upon the exercise of warrants, all subject to a 9.99% …

EMBC UPCOMING DEADLINE : The Gross Law Firm Alerts Embecta Corp. Stockholders of Securities Class Action - Contact the Firm

The Gross Law Firm has issued a notice to shareholders of Embecta Corp. (NASDAQ: EMBC) regarding a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements about its financial performance, particularly concerning its pen needle business, leading to a significant stock …

EMBC Stock Drop: Embecta Insulin Pen Issues Lead to 57% Stock Drop and Securities Fraud Class Action for Investors

|

Aarti Surfactants Ltd. Share Price Today: 11.39% Increase

Nectar Lifesciences sells Narbada unit assets for ₹11.22 crore

CT Automotive Expects Stronger Second Half Following Revenue Growth and Mexico Expansion

CT Automotive slumps 23% as costs bite despite 15% revenue growth

Earnings Flash (CTA.L) CT Automotive Group Reports H1 Revenue $62.1M

Octave Specialty Group to Report Q2 Earnings: What to Expect

Octave Specialty Group, Inc. OSG is expected to witness an improvement in its top and bottom lines when it reports second-quarter 2026 results on Aug. 6, after the closing bell. The Zacks Consensus Estimate for OSG's second-quarter revenues is pegged at $81 million, indicating …

Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP is reminding investors of Embecta Corp. (EMBC) about an upcoming August 17, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Embecta made materially false and misleading statements between November …